MedImmune

From Wikipedia, the free encyclopedia

MedImmune, LLC, headquartered in Gaithersburg, Maryland, became a wholly owned subsidiary of AstraZeneca in 2007. Since being acquired, MedImmune has remained a Maryland-based biotechnology development enterprise. It produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for $1.06 billion of its $1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004.

FluMist was approved for children 2 and older in 2007, but initially was approved only for healthy people ages 5 to 49, a significant limitation because it eliminated a significant market -- the millions of young children who find injections objectionable. Sales of FluMist fell short of analysts' expectations for the first two years the drug was sold. FluMist was initially sold in a frozen form, which was difficult for doctors to store.[1]

MedImmune conducted successful clinical trials for a new generation of FluMist needle-free vaccine, called CAIV-T, which was FDA approved in 2007, and is now the form offered on the market.

MedImmune reported a 16.6 million loss in 2005, and a $3.8 million loss the previous year for $1.14 billion in revenue. On April 23, 2007 it was announced MedImmune and AstraZeneca entered into a definitive agreement under which AstraZeneca intends to acquire MedImmune in an all cash transaction at $58 per share, or about $15.2 billion.[1]

In June 2007, the National Institutes of Health (NIH) began enrolling participants in a Phase 1 H5N1 study of an intranasal influenza vaccine candidate based on MedImmune's live, attenuated vaccine technology.[2]

[edit] Sources and notes

  1. ^ a b
  2. ^ MedImmune Press release MedImmune and National Institutes of Health Begin Clinical Testing of a Live, Attenuated Intranasal Vaccine Against an H5N1 Avian Influenza Virus published June 15, 2007

[edit] External links